Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476734 · ClinicalTrials.gov registry record
FDG-PET/CT Imaging as Early Predictor of DP
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 9
- Enrollment target
NCT02476734 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 9 participants.
The verdict
NCT02476734 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
In this study the investigators would like to describe FDG-PET/CT responses in patients who are receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects will undergo two FDG-PET/CTs. One performed within 6 weeks of CART-19 infusion and a repeat scan at about 1 month after infusion.
Interventions
- OTHER There is no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476734
The ClinicalTrials.gov registry entry for NCT02476734 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which There is no intervention is the first listed.
NCT02476734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476734 about?
NCT02476734 is a clinical study titled "FDG-PET/CT Imaging as Early Predictor of DP". In this study the investigators would like to describe FDG-PET/CT responses in patients who are receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects will undergo two FDG-PET/CTs. One perfo...
What is the current status of trial NCT02476734?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2014-08. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02476734?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT02476734?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.